PRRT3

Across TCGA pan-cancer cohorts, PRRT3 RNA differs between tumor and matched normal tissue in 11 of 18 cancer types tested, making tumor–normal expression one of PRRT3’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where PRRT3 RNA is repressed in tumor relative to normal tissue. In most cancer types PRRT3 is over-expressed in tumor, although a few such as KIRC and HNSC show the opposite, repressed pattern.

KIRC, LIHC, and HNSC are the cancer types where PRRT3 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in PRRT3 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Male	II,III,IV	−1.060	<.001	12	view →
LIHC	Female	II,III,IV	+0.817	<.001	9	view →
HNSC	All	II,III,IV	−0.552	.001	8	view →
BRCA	All	III,IV	+1.516	<.001	6	view →
KIRP	All	All	−0.590	.001	6	view →
COAD	All	All	+0.251	.001	5	view →
KICH	All	All	−0.754	.001	3	view →
LUAD	Female	All	+0.467	.017	3	view →
CHOL	All	All	+0.738	.001	2	view →
PRAD	All	All	+0.456	<.001	2	view →
THCA	Female	All	+0.339	.012	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 11 strongest of 11 lineages.

PRRT3–KIRC

Open the KIRC breakdown →